DuPont Genetics LLC

dupontgenetics.com

DuPont Genetics Rooted in the Northeast in early 2012. Pioneering the cannabis industry at the forefront ever since.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

news image

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More

INDUSTRIAL IMPACT

BEIGENE ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH INNORNA TO JOINTLY DISCOVER NOVEL MRNA THERAPIES

InnoRNA and BeiGene | July 07, 2022

news image

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...

Read More

RESEARCH

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More

INDUSTRIAL IMPACT

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

news image

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More
news image

CELL AND GENE THERAPY

BIO-TECHNE SIGNS LICENSE AGREEMENT WITH LUMINARY THERAPEUTICS FOR THE USE OF TCBUSTER™ FOR THE MANUFACTURING OF GENE-MODIFIED CELL THERAPIES

Bio-Techne | February 25, 2021

Bio-Techne Corporation today declared the signing of a license agreement with Luminary Therapeutics for the utilization of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne's proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing. Under the provisions of this agreement, Bio-Techne grants Luminary Therapeutics a non-exclusive license for TcBuster. Luminary Therapeutics will utilize TcBus...

Read More
news image

INDUSTRIAL IMPACT

BEIGENE ANNOUNCES STRATEGIC RESEARCH COLLABORATION WITH INNORNA TO JOINTLY DISCOVER NOVEL MRNA THERAPIES

InnoRNA and BeiGene | July 07, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotec...

Read More
news image

RESEARCH

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More
news image

INDUSTRIAL IMPACT

ADCENTRX AND AVANTGEN ENTER A NEW PARTNERSHIP WITH A THREE-YEAR, MULTI-TARGET COLLABORATION TO DISCOVER ANTIBODIES FOR NOVEL ANTIBODY-DRUG CONJUGATES

Adcentrx Therapeutics | February 15, 2022

Adcentrx Therapeutics a biotechnology company focused on accelerating breakthroughs in antibody drug conjugate ("ADC") therapeutic development, and AvantGen, a leader in the use of yeast display technology for human antibody discovery and optimization, announced today a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. Under the terms of the collaboration, Adcentrx will specify targets against whic...

Read More